Optimi Health Corp. OPTH 深 滬
已收盤 06-18 16:00:00 美东时间
5.025
+0.665
+15.25%
華盛通- 最 高5.75
- 今 開4.60
- 成交量 65.13万股
- 最 低 4.40
- 昨 收 4.36
- 總市值 2827.01万
- 52周最高 6.40
- 市盈率 靜 --
- 換手率 11.58%
- 52周最低 4.00
- 委 比 -91.57%
- 總股本 562.59万
- 歷史最高 6.40
- 量 比 4.51
- 振 幅 30.96%
- 歷史最低 4.00
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant...
06-16 20:34
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat...
06-09 00:54
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Corp. has secured naturally derived ibogaine for its Ibogaine Initiative, with plans to develop finished drug products in 50mg and 100mg encapsulated forms at its GMP facility in Canada. Ibogaine, prioritized for accelerated FDA review under a recent U.S. executive order, is being studied for treating PTSD, opioid use disorder, and traumatic brain injury. The company aims to supply standardized dosages to support research and clinic...
06-08 12:00
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
The Therapeutic Goods Administration (TGA) in Australia has updated its framework for psychedelic-assisted therapy (PAT), expanding therapist eligibility, allowing treatment in diverse settings, and enhancing scalability. Optimi Health Corp., a Canadian psychedelic pharmaceutical company, supplies MDMA for PTSD and psilocybin for treatment-resistant depression under the updated Authorized Prescriber (AP) scheme. Key changes include multidisciplin...
05-29 12:30
首日收盘|Optimi Health收涨2485.03%，最新总市值0.35亿美元
Optimi Health涨2485.03%，最新市值0.35亿美元；Lincoln International涨12.60%，最新市值22.97亿美元；Research Alliance III涨3.00%，最新市值0.94亿美元；AMASS Brands (Direct Listing)跌33.24%，最新市值1.27亿美元；
05-21 06:00
Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/Shr
Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"VANCOUVER, BC, May 20, 2026 /CNW/ - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage
05-20 23:34
Optimi Health prices $15M public offering and Nasdaq uplisting
Optimi Health (OPTHD) announced on Wednesday the pricing of its underwritten public offering in connection with the uplisting of its common shares to Nasdaq. The company is offering 2.4M common shares...
05-20 20:39
